LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "parpi" as a keyword



Photo from wikipedia

Emerging therapeutic modalities of PARP inhibitors in breast cancer.

Sign Up to like & get
recommendations! Published in 2018 at "Cancer treatment reviews"

DOI: 10.1016/j.ctrv.2018.05.014

Abstract: Inhibition of Poly (ADP-ribose) polymerase (PARP) has shown marked benefit for breast cancer with homologous recombination deficiency, whether driven by defects in BRCA1, BRCA2, or other pathway components. Since the initial approval of olaparib, a… read more here.

Keywords: benefit; platinum; parpi; breast cancer ... See more keywords
Photo by schluditsch from unsplash

Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors

Sign Up to like & get
recommendations! Published in 2020 at "Expert Opinion on Emerging Drugs"

DOI: 10.1080/14728214.2020.1773791

Abstract: ABSTRACT Introduction Poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated significant anticancer activity in cancers harboring homologous recombination deficiency (HRD), exemplified by high grade serous ovarian cancer (HGSC). PARP inhibitors (PARPi) are being used in women… read more here.

Keywords: parp inhibitors; treatment; parpi; ovarian cancer ... See more keywords

CBMT-19. THE ALTERNATIVE LENGTHENING OF TELOMERE (ALT) MECHANISM PROVIDES COLLATERAL SENSITIVITY TO LETHAL TELOMERIC FUSION INDUCED BY TRAPPING PARP INHIBITORS

Sign Up to like & get
recommendations! Published in 2019 at "Neuro-Oncology"

DOI: 10.1093/neuonc/noz175.141

Abstract: A subset of human tumors, including all IDH1-mutant astrocytomas, use a homologous recombination-based alternative lengthening of telomere (ALT) pathway to resolve telomeric dysfunction in the absence of TERT. Because ALT is not used by normal… read more here.

Keywords: parpi; alt mechanism; parp; alt ... See more keywords
Photo by benjaminlehman from unsplash

PO-494 Using functional genetic screens to understand resistance to PARPi in BRCA-deficient tumours

Sign Up to like & get
recommendations! Published in 2018 at "ESMO Open"

DOI: 10.1136/esmoopen-2018-eacr25.511

Abstract: Introduction Error-free repair of double-strand DNA breaks is achieved by homologous recombination (HR), and both BRCA1 and BRCA2 are crucial for this process. Inactivating germline mutations of BRCA1 and BRCA2 genes predispose to breast and… read more here.

Keywords: functional genetic; deficient; parpi; resistance ... See more keywords

Myeloid neoplasms post PARP inhibitors for ovarian cancer

Sign Up to like & get
recommendations! Published in 2023 at "International Journal of Gynecological Cancer"

DOI: 10.1136/ijgc-2022-004190

Abstract: The incidence of myeloid neoplasms following treatment with poly (ADP-ribose) polymerase inhibitors (PARPi) in patients with ovarian cancer has been gradually increasing over the last few years. The cumulative exposure to PARPi and the improved… read more here.

Keywords: parpi; ovarian cancer; myeloid neoplasms; neoplasms post ... See more keywords
Photo by nci from unsplash

STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer

Sign Up to like & get
recommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"

DOI: 10.1136/jitc-2022-005627

Abstract: Background Poly (ADP-ribose) polymerase (PARP) inhibition (PARPi) has demonstrated potent therapeutic efficacy in patients with BRCA-mutant ovarian cancer. However, acquired resistance to PARPi remains a major challenge in the clinic. Methods PARPi-resistant ovarian cancer mouse… read more here.

Keywords: parpi; ovarian cancer; resistance; parp inhibition ... See more keywords
Photo by alvarordesign from unsplash

Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper

Sign Up to like & get
recommendations! Published in 2022 at "Clinical Cancer Research"

DOI: 10.1158/1078-0432.ccr-22-0301

Abstract: Abstract Purpose: We hypothesized that inhibition and trapping of PARP1 alone would be sufficient to achieve antitumor activity. In particular, we aimed to achieve selectivity over PARP2, which has been shown to play a role… read more here.

Keywords: parpi; inhibitor; generation; parp1 ... See more keywords

Bepotastine sensitizes ovarian cancer to PARP inhibitors through suppressing NF-κB-triggered SASP in cancer-associated fibroblasts.

Sign Up to like & get
recommendations! Published in 2023 at "Molecular cancer therapeutics"

DOI: 10.1158/1535-7163.mct-22-0396

Abstract: Therapy-induced senescence (TIS) is common in tumor cells treated with poly (ADP-ribose) polymerase inhibitors (PARPis), and can serve as a promising target for improving PARPi efficacy. However, whether stromal components within the tumor microenvironment undergo… read more here.

Keywords: parpi; ovarian cancer; senescence; tumor ... See more keywords

Abstract 5610: [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-inhibitor drug-target engagement as a biomarker of response in ovarian cancer

Sign Up to like & get
recommendations! Published in 2023 at "Cancer Research"

DOI: 10.1158/1538-7445.am2023-5610

Abstract: Purpose: Poly(ADP-ribose) polymerase enzyme inhibitors (PARPi) have become the standard-of-care treatment for homologous recombination deficient (HRD) high-grade serous ovarian cancer (HGSOC). However, not all HRD tumors respond to PARPi and biomarkers to predict response are… read more here.

Keywords: ftt pet; response; cancer; parpi ... See more keywords
Photo by ldxcreative from unsplash

Abstract CT018: Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations

Sign Up to like & get
recommendations! Published in 2023 at "Cancer Research"

DOI: 10.1158/1538-7445.am2023-ct018

Abstract: Introduction: ATRi and PARPi combinations kill tumor cells via synergistic modulation of complementary DDR pathways but clinical utility is limited by overlapping toxicities. A genome-wide CRISPR-Cas9 screen identified DDR alterations that sensitize tumors to the… read more here.

Keywords: parpi; atri camonsertib; solid tumors; response ... See more keywords

Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS) Associated with PARP Inhibitors: A Real-World Analysis

Sign Up to like & get
recommendations! Published in 2020 at "Blood"

DOI: 10.1182/blood-2020-142069

Abstract: Introduction: Poly (ADP-ribose) polymerase inhibitors (PARPi's) represent a newer class of antineoplastic agents targeting cancers with defective DNA-damage repair. PARPi's indications include subtypes of ovarian, fallopian tube and primary peritoneal cancer as well as subsets… read more here.

Keywords: parpi; aml mds; mds; approval ... See more keywords